1 Using numerical modeling and simulation to assess the ethical

2 burden in clinical trials and how it relates to the proportion of

3 responders in a trial sample

4 SHORT TITLE

- 5 Ethical loss in randomized clinical trials
- 6
- 7 Jean-Pierre Boissel^{1*¶}, David Pérol^{2¶}, Hervé Décousus^{3¶}, Ingrid Klingmann^{4¶}, Marc
- 8 Hommel^{5¶}

9 **AFFILIATIONS**

- ¹Novadiscovery, Lyon, France, CSO, Emeritus Professor of Clinical Pharmacology
- ¹¹ ²Department of Biostatistics, Centre Léon Bérard, Lyon, France, Head
- ¹² ³INSERM, CIC 1408 F Crin, INNOVTE; CHU Saint-Etienne, Hôpital Nord, Service
- 13 Médecine Vasculaire et Thérapeutique, F-42055 Saint Etienne, France, Head.
- ⁴European Forum for Good Clinical Practice (EFGCP), Brussels, Belgium,
- 15 Chairwoman of the Board
- ⁵University Hospital Grenoble, EA 4407 AGEIS UGA, France, Emeritus Professor of
- 17 Neurology

18 *Corresponding Author

19 E-mail: jean-pierre.boissel@novadiscovery.com

20 These authors contributed equally to this work. All authors have reviewed the

21 manuscript

22 ABSTRACT

23 In order to propose a more precise definition and explore how to reduce ethical losses 24 in randomized controlled clinical trials (RCTs), we set out to identify trial participants 25 who do not contribute to demonstrating that the treatment in the experimental arm is 26 superior to that in the control arm. RCTs emerged mid-last century as the gold 27 standard for assessing efficacy, becoming the cornerstone of the value of new 28 therapies, yet their ethical grounds are a matter of debate. We introduce the concept of 29 unnecessary participants in RCTs, the sum of non-informative participants and non-30 responders. The non-informative participants are considered not informative with 31 respect to the efficacy measured in the trial in contrast to responders who carry all the 32 information required to conclude on the treatment's efficacy. The non-responders 33 present the event whether or not they are treated with the experimental treatment. The 34 unnecessary participants carry the burden of having to participate in a clinical trial 35 without benefiting from it, which might include experiencing side effects. Thus, these 36 unnecessary participants carry the ethical loss that is inherent to the RCT 37 methodology. On the contrary, responders to the experimental treatment bear its entire 38 efficacy in the RCT. Starting from the proportions observed in a real placebo-39 controlled trial from the literature, we carried out simulations of RCTs progressively 40 increasing the proportion of responders up to 100%. We show that the number of 41 unnecessary participants decreases steadily until the RCT's ethical loss reaches a 42 minimum. In parallel, the trial sample size decreases (presumably its cost as well), 43 although the trial's statistical power increases as shown by the increase of the chi-44 square comparing the event rates between the two arms. Thus, we expect that 45 increasing the proportion of responders in RCTs would contribute to making them 46 more ethically acceptable, with less false negative outcomes.

47

48 INTRODUCTION

49	Ethical loss in randomized controlled clinical trials (RCTs) is an intuitive and rather
50	vague concept, which can be outlined at a first glance as a loss of chance, i.e.
51	everything an individual either misses or experience as detrimental as a result of
52	participating in a RCT. The uncertainty associated with trial enrollment has two
53	opposite issues. In an attempt to address these two opposite uncertainties, Freedman
54	proposed the concept of "equipoise".[1] RCTs remain the gold standard for
55	evaluating the efficacy and safety of new therapies.[2,3] Despite their wide
56	acceptance and applying the principle of 'equipoise', some questions of ethics in
57	RCTs remain unanswered. There are various types of ethical concerns linked to
58	randomization: prior to launching a trial of a new treatment, randomizing participants
59	to conventional treatments that is deemed less effective is a breach of the equipoise
60	principle, just as happen with allocation to a placebo, or to a known sham treatment;
61	once the trial is completed, if the experimental treatment turns out to be either more
62	effective or less effective (or even potentially harmful), participants in the control arm
63	or those in the experimental arm, respectively, face a loss of chance. If the required
64	informed consent is usually presented as a measure to overcome [4] these issues, in
65	reality it potentially transfers part of these concerns from investigators to participants.
66	Several alternatives to traditional RCTs have been proposed recently to address some
67	of these ethical concerns: adaptive designs enabling planned interim analyses that can
68	lead to a reduction of the total number of randomized participants or to a deletion of
69	study arms with inefficient treatment regimens and re-randomization of subjects to the
70	more promising treatment arms; and external control arms that suppressed the need to
71	randomize participants to the 'conventional treatment'.[5,6]

72 It is known that when a new treatment is being trialed, some participants in the 73 treatment arm will present the event the treatment is supposed to prevent, as opposed 74 to the "responders", i.e., those showing the expected reaction to treatment. 75 Identification of responders is a timely and challenging issue that remains poorly 76 studied, mainly because it is difficult to predict how participants will respond to the 77 experimental treatment. But beyond the importance of identifying responders in the 78 era of personalized medicine, the consequences of enrolling non-responders in RCTs 79 remain unexplored.

Although intuitively, selecting responders in RCTs is a worthwhile endeavor, the benefit of designing trials that meet this goal remains unexplored. Further, there is a lack of consensus in recommending it. Large trials, recruiting with little constraints have been advocated and frequently undertaken.[7,8] Regulators advise that criteria over inclusion and exclusion criteria in phase III trials should be relaxed as much as possible,[9] while suggesting maintaining sufficient homogeneity, seeking for a compromise that is not easy to achieve.

87 The work presented here focus on the ethical issue arising from including non-

88 responders in RCTs. More precisely, the objective of our work is to show how RCT

simulations can be used to address the consequences of diluting the number of

90 responders in the trial sample. Our simulations do not aim at quantitatively defining

91 adequate parameters of an RCT but intend to draw upon the qualitative perception of

92 the issue of ethical loss linked to the current way of how RCTs are planned, especially

- 93 when it comes to eligibility criteria. To that extent, our approach focuses on treatment
- 94 efficacy. We postulate that identifying responders could reduce uncertainty and could
- 95 be viewed as an operational equipoise principle.

96 MATERIAL AND METHODS

97 **Overview**

98 Collected data from a published trial was used for initiating the simulations conducted 99 for the purpose of this study. The definitions of each category of trial participants 100 defined below were applied to allow for computing the required number of 101 participants for the five categories. The changes in different trial characteristics as a 102 function of the proportion of responders was explored, taking the published trial as 103 the point zero.

104 **Conceptual framework of this work**

105 The two separate objectives of a clinical trial

106 When one states that a trial is "aimed at demonstrating the efficacy of X in, for 107 example, preventing death in patients with type 2 diabetes", the statement has two 108 intertwined meanings, or objectives, one being qualitative, the other quantitative. 109 First, it means that the trial is expected to show that X is more effective than the 110 control in preventing death (qualitative objective), and second, that it will provide an 111 estimate of the effect size (quantitative objective). The two objectives are tightly 112 intertwined because the achievement of the first one depends, among others, on the 113 observed effect size. However, for the sake of our reasoning, these must be strictly 114 separated, focusing on the number of responders (a quantitative objective). Although 115 out of the scope of the work developed here, there are other, more fundamental, 116 reasons for separating these two objectives. Just to name two examples: while the 117 efficacy is a treatment property, which supports consideration of extrapolating the

- 118 context of use, the validity of the effect size estimate based on the difference between
- 119 the observed rates of the event in the two arms is limited to the trial itself.
- 120 "Responders", "non-responders", "non-informative", and "unnecessary"
- 121 participants
- 122 Definition of a responder

123 Let us assume that the expected effect of the treatment of interest is to prevent a 124 dichotomous (yes/no) event, such as death. In this instance, a responder is a patient 125 who would have presented the event the experimental therapy is supposed to prevent 126 if he/she had not been treated with this therapy, and who will not present it if treated 127 with the therapy. In parallel-arm design, RCT with mortality endpoints, responders 128 are subjects with a fatal outcome under control treatment (C) administration but who 129 are kept alive if administered the experimental treatment (T). The control treatment 130 can be the standard of care (SoC) alone, a competitor or a placebo, both on top of 131 SoE. Although it sounds simple, in practice, this definition of responders is to today 132 difficult, if not impossible, to apply: how to predict that a given patient is a 133 responder? Note the assumption that the experimental treatment is better than the 134 control, at least for a few participants, or even a single one.

135 Number of responders in a two-arm RCT

Let us use as an example a two-arm completed RCT with the number of event-free subjects and participants having presented the event as shown in Table 1. At baseline, the two study arms are supposed to be identical, thanks to randomization. Although in the real world, the blind randomizing process is aimed at producing two groups

- 140 identical on average, we will assume that all subjects included in the trial display
- 141 similar baseline characteristics, i.e. are exchangeable.
- 142 The event rates are defined as Rc = a/Nc and $R_T = b/N_T$ in the control and
- 143 experimental treatment groups, respectively. The experimental treatment efficacy is
- 144 measured by the absolute benefit, $AB = Rc R_T$, but other efficacy metrics have been
- also described.[6] A statistical test on the observed value of the chosen metrics
- 146 enables us to conclude on the materiality of the treatment efficacy. The metrics
- 147 absolute value and its corresponding confidence interval are used to translate the size
- 148 of the efficacy observed in the trial to a different setting.[10]
- 149 **Table 1.** Summary data of a completed RCT. *a*, *b*, *c*, *d* are number of patients in each

150 cell and Nc and NT the total number of patients in the control and the experimental

arms respectively

Control arm (C)	Experimental

treatment	arm	(T)
-----------	-----	-------------

Event	а	b
No event	С	d
Total	Nc	Nt

152 How many responders in an RCT?

153 Should the experimental treatment be effective, this translates in a true Rc greater 154 than the true R_T. Moving forwards, observed values are assumed as the true values. In 155 the experimental treatment arm, there are responders, who encompass the difference 156 in magnitude of effect compared to the control arm. Since all subjects included in the 157 trial are assumed identical, there is a responder counterpart in the control arm.

158 Designated 'potential' responders, unlike responders in the experimental therapy arm,

they will not benefit from participating in the trial.

160 Since all participants are assumed exchangeable, they are in fact identical and we can 161 apply the definition of responders given above. According to that same definition, the 162 number of responders in the experimental therapy arm is given by $d_1 = (\text{Rc} - \text{R}_T).\text{N}_T$. 163 In fact, they are among the 'd' participants in the experimental therapy arm who will 164 not develop the event (Table 1). The remaining of the 'd' patients, d_2 , are those who 165 would not have presented the event when not receiving the experimental treatment. 166 The total number of responders in the trial, i.e. the number of responders in the 167 experimental treatment arm plus the number of potential responders in the control 168 arm, is $(Rc - R_T)$. $(Nc + N_T)$.

169 *"Non-informative" and "unnecessary" participants*

170 We introduce the concept of unnecessary and non-informative participants in RCTs. 171 Non-informative participants are subjects who will not present the event regardless of 172 being treated or not with the experimental therapy. They are considered not 173 informative with respect to the efficacy measured in the trial as opposed to 174 responders, who carry all the information required to conclude on the treatment's 175 efficacy. On the other hand, unnecessary participants are all the subjects who do not 176 benefit from participating in the trial regarding the prevention of the event, that is to 177 say, non-responders and non-informative participants. Non-responders will present 178 the event whether treated or not with the experimental treatment. These unnecessary 179 participants carry the burden of having to participate in a clinical trial without 180 benefiting from it, which might include experiencing side effects. These various 181 categories are illustrated in Table 3, in the Results section.

182 How many non-responders in this RCT?

183	According to out	r definition of res	sponders, the nor	a-responders are	those subjects who
105	riccorung to ou	a definition of ite	spondens, and not	i responders dre	mobe budgeets who

- 184 would experience the event regardless of being administered the experimental
- 185 treatment or not. Their number in the experimental treatment arm is 'b' and a (Rc Rc)
- 186 R_T).Nc in the control group. Their total number is $(a + b) (\text{Rc} \text{R}_T)$.Nc.

187 How many non-informative and unnecessary participants are included in a trial?

188	Let us deal first with the primary objective of a RCT, which is to generate evidence to
189	support the efficacy, i.e. reduces the rate of the event of interest, of the experimental
190	treatment that happens when the observed difference in rates Rc - R_T is large enough
191	to rule out the play of chance. Looking at the figures in Table 1 from a purely
192	theoretical point of view, the gold standard statistical significance can be achieved,
193	among other means, by decreasing ' c ' and ' d ', the number of recruited subjects who
194	will not present the event, whatever the arm they have been randomly allocated to.
195	These ' $c + d$ ' participants do not carry any information regarding the primary
196	objective of the trial. Their main "role" in the trial is to provide a denominator value
197	for computing the rates, Rc and R_T . As noted above, the responders in the treatment
198	arm are hidden in 'd'. These $(Rc - R_T)$. N _T participants are in effect the only ones to
199	benefit from participating in the trial. Further, they carry the efficacy as captured in
200	the trial. For this reason alone, they must be counted apart. Participants $c + d$ - (Rc –
201	R_T). N_T are said "non-informative" for they do not contribute with real pharmacologic
202	effect from the experimental treatment. Elaborating on this same reasoning, the non-
203	responders are unnecessary participants for they do not bring into the trial a part of the
204	experimental treatment efficacy and they cannot (when they were allocated to the
205	control arm) or do not (experimental treatment arm) benefit from the treatment. In

fact, as shown later by the simulation, a 'perfect' trial does recruit only responders. In total, the number of unnecessary participants in clinical trial is $(c + (d - R_T.N_T)) + (a + b) - N_R$. Hence, we identified and defined four categories of participants in a trial, the last category of which being the sum of the two previous ones (see Table 3): responders, non-responders, non-informative and unnecessary participants, totaling the number of non-responders and non-informative participants.

212 Ethical losses and unnecessary participants

213 A source of recurring dispute within RCTs is their ethical acceptability. For an 214 individual, participating in an RCT can mean different types of ethical loss. For 215 example, exposure to side-effects, loss of access to standard care, or loss of access to 216 the best available and tailored treatment, or other more subtle, if not less detrimental, 217 types of ethical loss such as moral distress or the feeling of being misled by scientists, 218 pharmaceutical companies or even the society. There are, of course, benefits: best 219 care administered for free, chance to be given a new, more effective treatment, to 220 name a few. However, given the diversity of individuals, it is impossible to ensure a 221 positive benefit-loss balance for each participant. There is, therefore, an ethical 222 obligation to minimize the number of participants enrolled for whom the benefit-loss 223 balance would be negative. When the outcome of interest is deemed serious or life-224 threatening, and death is certainly the most serious one, the marginal benefits, 225 whatever they are, can be disregarded and ethical loss defined as any participant 226 enrolled in the trial who is not a responder. Therefore, the number of ethical losses is 227 $(Nc + N_T) - (Rc - R_T).N_T.$

228 A simplified trial summary data

229	A total of 7020 participants with type II diabetes were randomized to either the
230	control treatment (C), i.e. placebo, or empagliflozin (T) in the Empa-REG-Outcome
231	trial.[11] In this trial, twice as many participants were randomized to the experimental
232	treatment arm compared to a control arm. For the sake of simplicity, an assumption
233	was made that the experimental treatment had no other effect than preventing death,
234	which was not the case in the actual trial. And, instead of using the composite primary
235	endpoint used in the original trial, mortality from any cause was chosen, which is
236	straightforward in its validity and interpretation, in the Empa-REG trial and facilitates
237	simulations without altering the interpretation of their results. Mortality figures in this
238	simplified version of the original trial are given in Table 2.[11]

239 **Table 2**. Mortality figures in the Empa-REG-Outcome Trial [11]

	Placebo (C)	Treatment (T)	Total
Deceased	194	269	463
Alive	2139	4418	6557
Total	2333	4687	7020

240 Assumptions

For the sake of simplicity, a first assumption was made that the probability of death of non-responders was constant. This assumption does not apply in real life for a given disease, the untreated outcome probability varies from one subject to another, thus from one trial to another. Second, the only subgroup that remained the same in our

- simulations was that of the responders in the experimental treatment arm, i.e. those
- 246 participants who benefited from having been enrolled in the trial.

247 Simulations

248	Formulas developed in the previous sections were coded in an Excel spreadsheet and
249	applied to the mortality figures in the Empa-REG-Outcome Trial [11] (Table 2). RCT
250	simulations were carried out varying the proportion of responders. In contrast, as said
251	above, the number of participants in the subgroup of responders in the T arm was kept
252	constant (n=121, see below in the results section). It was assumed that, for
253	unnecessary participants, the "true" probability of death while untreated is the
254	observed death rate, Rc, in the control arm that remained constant across all simulated
255	trials. At each increment of the proportion of responders (0.025), a new RCT arises,
256	and the following values were computed from the new RCT's summary data (Table
257	1): the number of ethical losses, trial sample size, observed relative risk (RR), and
258	chi-square value for testing drug efficacy. The starting proportion is 1, a value
259	corresponding to the "perfect" trial where all enrolled participants are responders (see
260	below). The final proportion is 0.025, since a proportion that equals 0 results in
261	infinite values. Note that the proportion of responders in the Empa-REG-Outcome
262	trial is 0.023. Computations were done using an Excel spreadsheet. The numerical
263	values of the participants were rounded to the closest unit.

264 **RESULTS**

265	How many subjects per category are behind mortality information in the simplified
266	trial?

267	One of the measures of efficacy in RCTs is the relative risk (RR); in our simplified
268	trial, derived from the Empa-REG-Outcome trial,[11] the RR was 0.73. The
269	information on treatment efficacy is entirely carried by the responders. The
270	responders do not appear as such in Table 2, and little derivation is required to bring
271	them off, which is explained below. Other derivations and categories of participants
272	enrolled in the trial are also developed below, and their results are shown in Table 3.
273	The number of expected deaths in the T group if the participant had not received the
274	experimental treatment is $(194*(4687/2333)) = 390.[11]$ Thus, the number of
275	responders in the T group is $390 - 269 = 121$, which is another way to compute the
276	number of responders than the one given by definition itself, (Rc - R_T). N_T . Since the
277	size of the C group is about half the size of the T group, there are potential 60
278	responders in the C group, who, by definition, are among the 194 participants in the C
279	group with fatal event, i.e. death. Consequently, a total number of 181 participants
280	(121 + 60) with a responder profile have been recruited in the Empa-REG-Outcome
281	trial, representing only 2.3% of the enrolled participants.

These 181 responders and potential responders have a counterpart, the nonresponders. This counterpart is defined as those subjects enrolled in the trial arm T for whom the experimental treatment did not prevent death, i.e. all deceased participants in the T arm (269), plus those participants in the C group for whom the experimental treatment would not have prevented death, i.e. 134 (194 – 60). Note that participants

who stayed alive, whether treated or not, are neither responders nor non-responders, and considered neutral regarding the drug efficacy. The total of unnecessary participants equals 7020 - 181 = 6839, while the ethical losses (i.e., all the participants who do not benefit from enrolment in the trial regarding the primary outcome) add up to a total 6839 + 60, the potential responders in the C group. The range of participant categories defined against response to drug T is shown in Table 3 below.

In this trial, all those participants who did not benefit from the experimental treatment (i.e. 98.3% of all enrolled subjects) suffered ethical loss (i.e. 7020), minus the number of responders in the T group, 121. Note that the degree of ethical loss depends on the endpoints, with the maximum loss occurring if the endpoint is premature death.

298 **Table 3**. Demographic characteristics of participants.

Categories	Total N in the Empa-REG- outcome trial	Computation	Comments
Responders	181	121 (T group) + 60 (C group)	In the T arm, the number of responders is obtained by subtracting the observed number of deaths (269) from the expected number of deaths if T = C, 390 = 194*(4687/2333); in the C group 60 = 121*(2333/4687)
Non-	403	269 (T group) +	All deaths in T arm + all deaths in

responders		(194 – 60) (C	C arm minus the number of
		group)	responders in the P arm.
Non-	6436	2139 (number	
informative		of alive	
		participants in	
		the C group) +	
		4418 (number	
		of alive	
		participants in	
		the T group) –	
		121 (responders	
		in the treatment	
		arm)	
Total of	6839	6436 (non-	This is the total number of
unnecessary		informative) +	participants minus the T
participants		403 (non-	responders (121) and potential
		responders)	responders (60)
Ethical losses	6899	6839 (total	Number equals to total sample size
		unnecessary	less the number of responders (the
		participants) +	"true" responders, those
		60 (the	participants who beneficiate from
		potential	enrolment in the trial)
		responders in	
		the C group)	

299 Relations between the proportion of responders and trial characteristics

300	Relations between the percentage of responders and outstanding trial features (i.e.,
301	ethical losses, trial sample size, observed relative risk, and chi-square value for testing
302	drug efficacy) are shown in Figure 1 below. All other things being equal, especially
303	the responders and non-informative subject profiles, when the percentage of
304	responders in the trial sample increases from null to 100% (the "perfect" trial sample),
305	the ethical losses, the sample size, thus the overall trial cost, the observed relative risk
306	decrease, while the chi-square value increases. Since the sample size decreases, the
307	overall trial cost decreases, while the chi-square value increases, also increasing the
308	chance of demonstrating the experimental treatment's efficacy. The overall
309	conclusion from these results supports the intuitive conviction that efficacy is less
310	likely demonstrable when responders are insufficiently represented in the trial sample.
311	Figure 1. Relations between the proportion of responders in the trial sample and
312	major features of the trial.

313 The "perfect" randomized clinical trial

Were it possible to recruit only responders, this amounts to the perfect RCT: i) all treated participants who otherwise would have died will be alive by the end of the trial; ii) the number of subjects needed to achieve the sample size for randomization would be the lowest possible; iii) the ethical losses minimized. Here the ethical losses amount to 60 (33.4%) of all randomized subjects (Table 4). We notice that even in this "perfect" RCT, there is an inescapable, although minimized, ethical loss.

320 **Table 4**. Ethical losses

	С	Т	
Deceased	60	0	60
Alive	0	121	121
	60	121	181

321 *"Less perfect" trials*

322 No matter how much we would like it to happen, identifying responders with 100% 323 accuracy is nothing but a pipe dream. Among the many reasons for this is the simple 324 fact that the drug has not yet been tested in humans in the anticipated context of use in 325 real life, preventing any researcher from inferring the responder profile. However, 326 while work is ongoing to overcome this hurdle and identify responders' profile ahead 327 of the trial as accurately as possible, we explored the consequences of progressively 328 increasing the proportion of responders in our simulated example in Figure 1, 329 showing that ethical losses, the required trial sample size and the relative risk all 330 decrease, while the probability of ascertaining trial significance increases. 331 DISCUSSION

332 The results and their derivation share a series of disruptive points that deserve333 discussion.

334 Limitations of this study

Our study has some limitations relating to the theoretical nature of the approach usedto conduct the simulations presented here. Could these limitations reduce the impact

337	of the results obtained? In a real trial, participants are not interchangeable; they may
338	withdraw or disappear, may take the treatment incorrectly, and may have been
339	wrongly classified as eligible. For simplicity, it was decided to dismiss these potential
340	limitations. Taking into account the non-compliance with the trial procedures and
341	treatment would lead to different figures in Table 3 but would not change the
342	direction of the results. Moreover, we have made it clear from the outset that the study
343	objective was of qualitative and not quantitative nature.
344	The impact of the participant interchangeability hypothesis is more difficult to assess.
345	Imagine that the individuals included in the trial are grouped into clusters of similar
346	characteristics. Within a cluster, participants are interchangeable. From one cluster to
347	another, the proportion of responders might vary. If we apply the same approach to
348	each cluster, the overall result will remain qualitatively the same.

349 Ambiguity of clinical trial objectives

- 350 A trial said to be "aimed at demonstrating the efficacy of X on preventing death in
- 351 patients with type 2 diabetes", has two intertwined meanings. First, the trial is
- 352 expected to show that X is more effective than the control, and second, that it will
- 353 provide an estimate of the effect size. We have shown that observed efficacy in the
- trial and therefore the chance to demonstrate efficacy is dependent on the proportion
- 355 of responders, whereas the genuine efficacy of the experimental treatment is a
- 356 property that is independent of this proportion.

357 Is treatment efficacy carried by responders in full?

- 358 Traditionally, response to treatment and the treatment effect size are the cornerstones
- 359 of efficacy demonstration for any RCT. Such assumptions have two major

361 applying the responder paradigm, as shown here, efficacy is no longer dil	luted. For the
362 recruited subjects, the tested treatment is or is not effective, it is a dichoto	omous
363 (yes/no) response. While such a way of looking at efficacy is acceptable	for a binary
364 event such as death or relapse of HBV infection, for example, it seems le	ess relevant
365 for a continuous outcome such as pain. However, even pain can be binari	ized if we
take into account each participant's own threshold of pain acceptability.	Second,
367 translation to other populations is often achieved by applying the measure	ed relative
368 risk. With this responder paradigm, efficacy indices obtained on one pop	oulation are
369 irrelevant to another population (see panel C, Figure 1) because it is likel	ly that the
370 fraction of responders will vary between populations, and so will the rela	ative risk and
all other indices. The point here is that the proportion of subjects not at ri	isk and
372 responders randomized in either arm will change, and thus the relative ris	sk will
373 change accordingly. This is a consequence of the Effect Model (EM) law	v, a principle
that has been verified both empirically and theoretically.[12] The EM law	w says that
375 the absolute benefit in a population varies as a function of individual or s	sub-group
376 rate of events (Rc), whatever is the treatment of interest. Therefore, both	Rt and Rc
377 vary, and so does the relative risk. The relative risk remains constant in o	one instance
378 only: when the EM is linear, which seems quite infrequent.	

379 Non-informative and/or unnecessary participant = ethical loss; how does the 380 equation fare?

381 Central in the argumentation is the idea that data on efficacy in an RCT is only carried382 by the responders. This proportion of responders is the taproot of the ethical losses

since, for those who are not responders, the burden of participating in a trial is not

- 384 offset by the benefit expected.
- 385 Is focusing on the unnecessary trial participants a way to address ethical issues in
- 386 *an RCT?*
- 387 As exposed in the introduction, the uncertainty raised from enrolling individuals in an 388 RCT has two opposite uncertainties. On the one hand, the standard treatment is 389 possibly less effective or more harmful than the experimental treatment. On the other, 390 the standard treatment is known to be effective, whereas the efficacy of that in the 391 experimental arm is postulated. To help handle the two opposite uncertainties, 392 Freedman proposed the concept of "equipoise".[1] An investigator can enroll subjects 393 in an RCT if there is genuine uncertainty about the preferable treatment.[13] It is 394 interesting to note that in a review of childhood oncology trials, the odds ratio for 395 survival was 0.96, suggesting that the equipoise has been respected. [14] This finding 396 points out to a limitation of this equipoise principle: is it ethical to launch a trial if the 397 evidence in favor of an expected superior efficacy of the experimental treatment 398 against the control is almost nil? Our results show that identifying responders would 399 in fact reduce uncertainty and can be viewed as an operational equipoise principle.
- 400 Is the "perfect" RCT "fully" ethical?

When we considered the "perfect" RCT, with 100% of responders, we noted that the
60 participants randomized to the control arm, had all deceased by the end of the trial:
the ethical loss for this "perfect" RCT was 33%. Thus, even a perfect randomized trial
cannot annul the number of unnecessary participants. This fact deserves three
comments: i) the ethical loss can be reduced by lowering the fraction of subjects

- 406 randomized into the control arm; ii) however, the ethical loss in a RCT cannot be
- 407 avoided; iii) increasing the proportion of responders implies that a reliable tool is
- 408 required to enable their selection.
- 409 Other ethical issues remain for responders such as the amount and type (e.g., invasive
- 410 investigations) of data collected, number of investigation time-points, confidentiality,
- 411 and informed consent process.

412 Selection of responders for enrolment in RCT: neither new nor easy

- 413 We demonstrated that selecting responders in RCT is of benefit to overcome ethical
- 414 limitations of RCTs but also to address other practical issues, such as the trial sample
- 415 size. Sequential designs were long proposed to reduce the number of subjects
- 416 enrolled. [15,16] Increasing the proportion of responders is one of the arguments in
- 417 favor of adaptive designs.[5] But the issue remains, how to select responders ahead of
- 418 trial onset or more often during the trial. Several ways have been explored: responders
- 419 identified with markers of response,[17] good compliers as assessed in a run-in
- 420 phase,[18] play-the-winner,[19] discontinuation for non-responders or considerably
- 421 improved participants in a run-in phase, [20] post-hoc selection, for instance, non-
- 422 responders discontinuation trial designs.[21] All these attempts have not been widely
- 423 adopted either because they were not proven successful, or because they are difficult
- to implement or because they were considered unethical.[22]
- 425 A tool that can identify responders before enrolment is clearly needed. More
- 426 specifically, the false positive error rate must be 0. We are still far from achieving
- 427 fully reliable tools, although potential solutions as to how they could be designed are
- 428 now available.[23] Nevertheless, if this is achieved, the permanence of RCT as the

429 gold standard will be more strongly and more rightly challenged. Most importantly, 430 the design and undertaking of RCTs will have to change as a result. The availability 431 of tools for selecting responders will raise two challenging issues: the validation and 432 implementation of responder selection. The reduced sample size is an additional 433 consequence to bear in mind. Further, should such a tool be successfully designed, 434 this would undoubtedly change the applicability of the concept of personalized 435 medicine concept as it is currently known. 436 Conclusion 437 The simulation reported here confirms that increasing the proportion of responders in 438 a RCT is worthwhile on ethical grounds, mainly because it reduces the number of 439 subjects enrolled who do not provide information on treatment efficacy.

440 We claim that the low proportion of responders is parallel to and a marker of the 441 uncertainty relating to the experimental treatment efficacy ahead of trialing new 442 drugs. Scannel and Bosley have shown that, currently, drug development processes 443 are poorly informative.[24] According to new policies issued by the FDA and EMA, 444 performing *in silico* clinical trials might be a solution to improve the efficiency of 445 R&D by reducing uncertainty across all the stages.[25-27] Individualized computer 446 simulations could become therefore a valuable tool to identify responders ahead of 447 designing RCT.[12,28]

448 ACKNOWLEDGMENTS

449 Data resulting from simulations are available as supplementary material.

450 **Competing Interest Statement**

- 451 All authors have completed the Unified Competing Interest form (available on request
- 452 from the corresponding author) and declare: no support from any organization for the
- 453 submitted work [or describe if any]; no financial relationships with any organizations
- that might have an interest in the submitted work in the previous three years [or
- 455 describe if any], no other relationships or activities that could appear to have
- 456 influenced the submitted work [or describe if any].

457 Author Contributions

- 458 As the guarantor of the study, Jean-Pierre Boissel contributed to the
- 459 conceptualization, data curation, formal analysis, and software as well as the
- 460 development of the methodology and the original draft preparation. He also
- 461 contributed, together with Marc Hommel, Ingrid Klingmann and David Pérol, to the
- 462 management and coordination of the research activity planning and activation. Marc
- 463 Hommel was responsible for the funding acquisition. All authors contributed equally
- to the validation, visualization, and review and editing of the manuscript submitted
- 465 for publication.

466 Thank-you's

467 The authors thank Rita Moreira da Silva and Paulo Pacheco for their contribution to468 the editing and formatting of the manuscript.

469

470 **REFERENCES**

471	1.	Freedman B. Equipoise and the ethics of clinical research. N Engl J Med.
472		1987;317: 141–5 doi: 10.1056/NEJM198707163170304
473	2.	Saad ED, Paoletti X, Burzykowski T, Buyse M. Precision medicine needs
474		randomized clinical trials. Nat Rev Clin Oncol. 2017;14: 317-23. doi:
475		10.1038/nrclinonc.2017.8.
476	3.	van Rosmalen BV, Alldinger I, Cieslak KP, Wennink R, Clarke M, Ali UA, et
477		al. Worldwide trends in volume and quality of published protocols of
478		randomized controlled trials. PLoS One. 2017;12: e0173042. doi:
479		10.1371/journal.pone.0173042.
480	4.	Levine R, Lebacqz, K. Some ethical considerations in clinical trials. Clin
481		Pharmacol Ther. 1979;25: 728–41.
482	5.	Brown CH, Have TRT, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive
483		designs for randomized trials in public health. Annu Rev Public Health.
484		2009;30: 1-25. doi: 10.1146/annurev.publhealth.031308.100223.
485	6.	Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and External Controls in
486		Clinical Trials – A Primer for Researchers. Clin Epidemiol. 2020;12: 457–
487		467. doi: 10.2147/CLEP.S242097.
488	7.	Remington RD. Design, and management of large multicenter clinical trials
489		Clin Pharmacol Ther. 1978; 60:244-249
490	8.	Peto R, Collins R, Gray R. Large-scale randomized evidence: large simple
491		trials and overviews of trials J Clin Epidemiol.1995;48:23-40. doi:
492		10.1016/0895-4356(94)00150-о.

493	9. Statistical Principals for Clinical Trials. Available from:
494	https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-
495	statistical-principles-clinical-trials-step-5_en.pdf
496	10. Boissel JP, Cogny F, Marko N, Boissel FH. From Clinical Trial Efficacy to
497	Real-Life Effectiveness: Why Conventional Metrics do not Work. Drugs Real
498	World Outcomes. 2019;6: 125-32. doi: 10.1007/s40801-019-0159-z.
499	11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
500	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
501	N Engl J Med. 2015;373: 2117–28. doi: 10.1056/NEJMoa1504720.
502	12. Boissel JP, Cucherat M, Nony P, Chabaud S, Gueyffier F, Wright JM, et al.
503	New insights on the relation between untreated and treated outcomes for a
504	given therapy effect model is not necessarily linear. J Clin Epidemiol.
505	2008;61: 301-7. doi: 10.1016/j.jclinepi.2007.07.007.
506	13. Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to
507	ensure scientific and ethical validity in clinical research. Curr Oncol Rep.
508	2001;3: 389–95. doi: 10.1007/s11912-001-0024-5.
509	14. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, et al; Children's
510	Oncology Group. Are experimental treatments for cancer in children superior
511	to established treatments? Observational study of randomised controlled trials
512	by the Children's Oncology Group. BMJ. 2005;331: 1295. doi:
513	10.1136/bmj.38628.561123.7C.
514	15. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical
515	modelling of patient subpopulations: Efficient designs of Phase II oncology
516	clinical trials. Clin Trials. 2013;10: 720-34. doi: 10.1177/1740774513497539.

517	16. Whitehead J. A unified theory for sequential clinical trials. Stat Med. 1999;18:

- 518 2271-86. doi: 10.1002/(sici)1097-0258(19990915/30)18:17/18<2271::aid-
- 519 sim254>3.0.co;2-z.
- 520 17. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, et al.
- 521 Comprehensive screening of target molecules by next-generation sequencing
- 522 in patients with malignant solid tumors: guiding entry into phase I clinical
- 523 trials. Mol Cancer. 2016;15: 73. doi: 10.1186/s12943-016-0553-z.
- 524 18. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect
- 525 of the run-in on the power of the Physicians' Health Study. Stat Med. 1991;10:
- 526 1585–93 doi: 10.1002/sim.4780101010.
- 527 19. Rosenberger W. Randomized play-the-winner clinical trials: review and
- recommendations. Control Clin Trials. 1999;20: 328–42 doi: 10.1016/s01972456(99)00013-6.
- 530 20. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al.
- 531 Phase II placebo-controlled randomized discontinuation trial of sorafenib in
- 532 patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 2505–
- 533 12. doi: 10.1200/JCO.2005.03.6723.
- 534 21. Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, et al.
- 535 Adaptive Randomization of Neratinib in Early Breast Cancer. 2016;375: 11–
- 536 22. doi: 10.1056/NEJMoa1513750.
- 537 22. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al.
- 538 Overview, hurdles, and future work in adaptive designs: perspectives from a
- 539 National Institutes of Health-funded workshop. Clin Trials. 2012;9: 671–80
- 540 doi: 10.1177/1740774512461859.

541

541	23. Boissel JP, Kahoul R, Marin D, Boissel FH. Effect model law: an approach for
542	the implementation of personalized medicine. J. Pers Med. 2013;3: 177-90.
543	doi: 10.3390/jpm3030177.
544	24. Scannell JW, Bosley J. When Quality Beats Quantity: Decision Theory, Drug
545	Discovery, and the Reproducibility Crisis. PLoS One. 2016;11: e0147215. doi:
546	10.1371/journal.pone.0147215.
547	25. Model Informed Drug Development Pilot Program. Available from:
548	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentReso
549	urces/ucm600311.htm.
550	26. Madabushi R, Benjamin JM, Grewal R, Pacanowski MA, Strauss DG, Wang
551	Y, Zhu H, Zineh I. The US Food and Drug Administration's Model-Informed
552	Drug Development Paired Meeting Pilot Program: Early Experience and
553	Impact. Clin Pharmacol Ther. 2019;106: 74-8. doi: 10.1002/cpt.1457.
554	27. Musuamba FT, Bursi R, Manolis E, Karlsson K, Kulesza A, Courcelles E,
555	Boissel JP, Lesage R, Crozatier C, Voisin EM, Rousseau CF, Marchal T,
556	Alessandrello R, Geris L. Verifying and Validating Quantitative Systems
557	Pharmacology and In Silico Models in Drug Development: Current Needs,
558	Gaps, and Challenges. CPT Pharmacometrics Syst Pharmacol. 2020;9: 195-
559	97. doi: 10.1002/psp4.12504.
560	28. Viceconti M, Henney A, Morley-Fletcher E. In silico Clinical trials: how
561	computer simulation will transform the biomedical industry. Int J Clin Trials.
562	2016;3: 37-46. doi:10.13140/RG.2.1.2756.6164.






Figure 1 panel B




Figure 1 panel C

Percentage of responders and trial relative risk (RR)




Figure 1 panel D




Figure 1 Relations between the proportion of responders in the trial sample and major

features of the trial

Panel A, shows the linear decrease of the ethical losses expressed in percentage of unnecessary patients with the increase of the percentage of responders. Panel B, keeping the number of responders in the T group constant at n=121, the sample size drops abruptly from more than 7,000 to less than 1,000 when the responder percentage increases up to about 20% to then flatten until the "perfect" trial status is reached, meaning that only responders are enrolled. Panel C, the relative risk decreases rapidly until the responder percentage reaches about 40%, from less than 0.8 to about 0. Panel D, the chi-square value of the comparison test of mortality rates between placebo and treatment groups increases linearly as the percentage of responders increases. The probability of ascertaining significance increases as well.